Lista de obras -

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo

artículo científico publicado en 2007

An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies

artículo científico publicado en 2014

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

artículo científico publicado en 2010

Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox ⬇️

artículo científico publicado el 15 de octubre de 2011

BL22 and lymphoid malignancies

artículo científico publicado en 2006

Bendamustine and rituximab in relapsed and refractory hairy cell leukemia

artículo científico publicado en 2013

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation

artículo científico publicado en 2011

Characterization of CD22 expression in acute lymphoblastic leukemia

artículo científico publicado en 2015

Cladribine Analogues via O⁶-(Benzotriazolyl) Derivatives of Guanine Nucleosides

artículo científico publicado en 2015

Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia

artículo científico publicado en 2013

Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome

artículo científico publicado en 2014

Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model

artículo científico publicado en 2014

Evidence of canonical somatic hypermutation in hairy cell leukemia ⬇️

artículo científico publicado el 2 de marzo de 2011

Expression of the muscle-associated gene MYF6 in hairy cell leukemia

artículo científico publicado en 2020

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

artículo científico publicado en 2005

Immunobiological treatments of hairy-cell leukaemia

artículo científico publicado en 2003

Immunoconjugates in the management of hairy cell leukemia

artículo científico publicado en 2015

Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies

artículo científico publicado en 2005

Immunotoxin therapy of hematologic malignancies

artículo científico publicado en 2003

Immunotoxin treatment of cancer

artículo científico publicado en 2007

Immunotoxins in the treatment of hematologic malignancies

artículo científico publicado en 2006

Immunotoxins in the treatment of refractory hairy cell leukemia

artículo científico publicado en 2006

Impact of telomere length on survival in classic and variant hairy cell leukemia

artículo científico publicado en 2015

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

artículo científico publicado en 2002

In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin

artículo científico publicado en 2004

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

artículo científico publicado en 2021

New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.

artículo científico publicado en 2005

Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments

artículo científico publicado en 2002

PRAME expression in hairy cell leukemia

artículo científico publicado en 2008

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia

artículo científico publicado en 2012

Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia

artículo científico publicado en 2013

Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma.

artículo científico publicado en 2012

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

artículo científico publicado en 2011

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

artículo científico publicado en 2012

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

artículo científico publicado en 2014

Recombinant immunotoxins for the treatment of haematological malignancies

artículo científico publicado en 2004

Recombinant immunotoxins for treating cancer

artículo científico publicado en 2004

Recombinant toxins for the treatment of cancer

artículo científico publicado en 2003

Removing a hair of doubt about BRAF targeting

artículo científico publicado en 2015

Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera

artículo científico publicado en 2006

Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.

artículo científico publicado en 2006

Soluble CD22 as a tumor marker for hairy cell leukemia

artículo científico publicado en 2008

Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

artículo científico publicado en 2011

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach

artículo científico publicado en 2014

The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

artículo científico publicado en 2011

The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan

artículo científico publicado en 2011

Thrombotic Microangiopathy with Targeted Cancer Agents ⬇️

artículo científico publicado el 3 de agosto de 2011

Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates ⬇️

artículo científico publicado el 15 de octubre de 2011

VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy

artículo científico publicado en 2009

Variables in the quantification of CD4 in normals and hairy cell leukemia patients ⬇️

artículo científico publicado el 1 de enero de 2011

Lista de obras de

Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells in vivo

An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies

Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial

Antibody Fusion Proteins: Anti-CD22 Recombinant Immunotoxin Moxetumomab Pasudotox ⬇️

BL22 and lymphoid malignancies

Bendamustine and rituximab in relapsed and refractory hairy cell leukemia

Both variant and IGHV4-34-expressing hairy cell leukemia lack the BRAF V600E mutation

Characterization of CD22 expression in acute lymphoblastic leukemia

Cladribine Analogues via O⁶-(Benzotriazolyl) Derivatives of Guanine Nucleosides

Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia

Class II human leucocyte antigen DRB1*11 in hairy cell leukaemia patients with and without haemolytic uraemic syndrome

Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model

Evidence of canonical somatic hypermutation in hairy cell leukemia ⬇️

Expression of the muscle-associated gene MYF6 in hairy cell leukemia

HA22 (R490A) is a recombinant immunotoxin with increased antitumor activity without an increase in animal toxicity.

Immunobiological treatments of hairy-cell leukaemia

Immunoconjugates in the management of hairy cell leukemia

Immunoglobulin superfamily receptor translocation associated 2 protein on lymphoma cell lines and hairy cell leukemia cells detected by novel monoclonal antibodies

Immunotoxin therapy of hematologic malignancies

Immunotoxin treatment of cancer

Immunotoxins in the treatment of hematologic malignancies

Immunotoxins in the treatment of refractory hairy cell leukemia

Impact of telomere length on survival in classic and variant hairy cell leukemia

Improved cytotoxic activity toward cell lines and fresh leukemia cells of a mutant anti-CD22 immunotoxin obtained by antibody phage display.

In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin

Long term follow-up of a phase II study of cladribine with concurrent rituximab with hairy cell leukemia variant

New monoclonal antibodies to mesothelin useful for immunohistochemistry, fluorescence-activated cell sorting, Western blotting, and ELISA.

Novel anti-CD30 recombinant immunotoxins containing disulfide-stabilized Fv fragments

PRAME expression in hairy cell leukemia

Phase I trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox (CAT-8015 or HA22) in patients with hairy cell leukemia

Quantification of expression of antigens targeted by antibody-based therapy in chronic lymphocytic leukemia

Radiation therapy for the management of patients with HTLV-1-associated adult T-cell leukemia/lymphoma.

Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes.

Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopes

Recombinant immunotoxins for the treatment of haematological malignancies

Recombinant immunotoxins for treating cancer

Recombinant toxins for the treatment of cancer

Removing a hair of doubt about BRAF targeting

Sandwich ELISAs for soluble immunoglobulin superfamily receptor translocation-associated 2 (IRTA2)/FcRH5 (CD307) proteins in human sera

Selective elimination of human regulatory T lymphocytes in vitro with the recombinant immunotoxin LMB-2.

Soluble CD22 as a tumor marker for hairy cell leukemia

Synergistic antitumor activity of anti-CD25 recombinant immunotoxin LMB-2 with chemotherapy.

The bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) blocks hairy cell leukaemia survival, proliferation and B cell receptor signalling: a new therapeutic approach

The cytotoxicity of anti-CD22 immunotoxin is enhanced by bryostatin 1 in B-cell lymphomas through CD22 upregulation and PKC-βII depletion.

The improvement of an anti-CD22 immunotoxin: conversion to single-chain and disulfide stabilized form and affinity maturation by alanine scan

Thrombotic Microangiopathy with Targeted Cancer Agents ⬇️

Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates ⬇️

VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy

Variables in the quantification of CD4 in normals and hairy cell leukemia patients ⬇️